Vifor Pharma (SIX Swiss Exchange:VIFNI) (SIN:CH0364749348) disclosed on Monday that it has agreed to acquire the priority review voucher (PRV) from US Food and Drug Administration (FDA).
The company stated that the PRV entitles the holder to obtain priority review for a New Drug Application or Biologics License Application thereby reducing the target review time and potentially leading to a faster approval.
This transaction is subject to customary closing conditions and clearance under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.
Headquartered in Switzerland, the pharmaceuticals company is engaged in iron deficiency, nephrology and cardio-renal therapies. It said it strives to help patients around the world with severe and chronic diseases to lead better, healthier lives.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT